BACKGROUND: Standard surgical treatment for women with stage IB1 cervical cancer consists of radical hysterectomy. This study assesses survival outcomes of those treated with less radical surgery (LRS; conization, trachelectomy, simple hysterectomy) compared to more radical surgery (MRS; modified radical, radical hysterectomy). METHODS: Using the Surveillance, Epidemiology and End Results database, we identified women <45 years with FIGO stage IB1 cervical cancer diagnosed from 1/1998 to 12/2012. Only those who underwent lymph node (LN) assessment were analyzed. Disease-specific survivals (DSSs) of LRS were compared with those of MRS. RESULTS: Of 2571 patients, 807 underwent LRS and 1764 underwent MRS, all with LN assessment. For LRS vs. MRS, 28% vs. 23% were diagnosed with adenocarcinoma (p = 0.024), 31% vs. 39% had G3 disease (p < 0.001), 40% vs. 45% had tumor size >2 cm (p < 0.001), and 27% vs. 29% received adjuvant radiation therapy (p = 0.005). Median follow-up was 79 months (range, 0-179). Ten-year DSS for LRS vs. MRS was 93.5% vs. 92.3% (p = 0.511). There was no difference in 10-year DSS when stratified by tumor size ≤2 cm (LRS 95.1% vs. MRS 95.6%, p = 0.80) or > 2 cm (LRS 90.1% vs. MRS 88.2%, p = 0.48). Factors independently associated with increased risk of death included adenosquamous histology (HR 2.37), G3 disease (HR 2.86), tumors >2 cm (HR 1.82), and LN positivity (HR 2.42). Compared to MRS, LRS was not associated with a higher risk of death. CONCLUSIONS: In a select group of young women with stage IB1 cervical cancer, LRS compared to MRS does not appear to compromise DSS.
BACKGROUND: Standard surgical treatment for women with stage IB1cervical cancer consists of radical hysterectomy. This study assesses survival outcomes of those treated with less radical surgery (LRS; conization, trachelectomy, simple hysterectomy) compared to more radical surgery (MRS; modified radical, radical hysterectomy). METHODS: Using the Surveillance, Epidemiology and End Results database, we identified women <45 years with FIGO stage IB1cervical cancer diagnosed from 1/1998 to 12/2012. Only those who underwent lymph node (LN) assessment were analyzed. Disease-specific survivals (DSSs) of LRS were compared with those of MRS. RESULTS: Of 2571 patients, 807 underwent LRS and 1764 underwent MRS, all with LN assessment. For LRS vs. MRS, 28% vs. 23% were diagnosed with adenocarcinoma (p = 0.024), 31% vs. 39% had G3 disease (p < 0.001), 40% vs. 45% had tumor size >2 cm (p < 0.001), and 27% vs. 29% received adjuvant radiation therapy (p = 0.005). Median follow-up was 79 months (range, 0-179). Ten-year DSS for LRS vs. MRS was 93.5% vs. 92.3% (p = 0.511). There was no difference in 10-year DSS when stratified by tumor size ≤2 cm (LRS 95.1% vs. MRS 95.6%, p = 0.80) or > 2 cm (LRS 90.1% vs. MRS 88.2%, p = 0.48). Factors independently associated with increased risk of death included adenosquamous histology (HR 2.37), G3 disease (HR 2.86), tumors >2 cm (HR 1.82), and LN positivity (HR 2.42). Compared to MRS, LRS was not associated with a higher risk of death. CONCLUSIONS: In a select group of young women with stage IB1cervical cancer, LRS compared to MRS does not appear to compromise DSS.
Authors: J L Benedet; F Odicino; P Maisonneuve; U Beller; W T Creasman; A P Heintz; H Y Ngan; M Sideri; S Pecorelli Journal: J Epidemiol Biostat Date: 2001
Authors: A Covens; B Rosen; J Murphy; S Laframboise; A D DePetrillo; G Lickrish; T Colgan; W Chapman; P Shaw Journal: Gynecol Oncol Date: 2002-01 Impact factor: 5.482
Authors: G. Comerci; B. S. Bolger; G. Flannelly; M. Maini; A. de Barros Lopes; J. M. Monaghan Journal: Int J Gynecol Cancer Date: 1998-01 Impact factor: 3.437
Authors: Raimund Winter; Josef Haas; Olaf Reich; Rudolf Koemetter; Karl Tamussino; Manfred Lahousen; Edgar Petru; Hellmuth Pickel Journal: Gynecol Oncol Date: 2002-02 Impact factor: 5.482
Authors: Anil K Sood; Ingrid Nygaard; Mark S Shahin; Joel I Sorosky; Susan K Lutgendorf; Satish S C Rao Journal: J Am Coll Surg Date: 2002-10 Impact factor: 6.113
Authors: A Covens; B Rosen; J Murphy; S Laframboise; A D DePetrillo; G Lickrish; T Colgan; W Chapman; P Shaw Journal: Gynecol Oncol Date: 2001-05 Impact factor: 5.482
Authors: Carlos Parra-Herran; Anais Malpica; Esther Oliva; Gian Franco Zannoni; Pedro T Ramirez; Joseph T Rabban Journal: Int J Gynecol Pathol Date: 2021-03-01 Impact factor: 3.326
Authors: Christos Tsaousidis; Bernhard Kraemer; Stefan Kommoss; Andreas Hartkopf; Sara Brucker; Katrin Neis; Juergen Andress; Felix Neis Journal: Reprod Sci Date: 2021-11-29 Impact factor: 3.060
Authors: Antoni Llueca; Maria Victoria Ibañez; Aureli Torne; Antonio Gil-Moreno; Angel Martin-Jimenez; Berta Diaz-Feijoo; Anna Serra; Maria Teresa Climent; Blanca Gil-Ibañez Journal: J Pers Med Date: 2022-06-30